IGF-I’s effects on the liver may involve mechanisms, such as improved insulin sensitivity, as IGF-I deletion from the liver results in insulin resistance [32], suggesting that increased levels of circulating IGF-I can alleviate MASH partly by enhancing insulin sensitivity. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatohepatitis.